Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451958 · ClinicalTrials.gov registry record · Phase 3
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
A Phase 3 study of Prostate Cancer, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 386
- Enrollment target
- 20
- Study locations
NCT00451958 is a Phase 3 study of Prostate Cancer that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 386 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00451958, a Phase 3 study of Prostate Cancer, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 386 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
Conditions Studied
Interventions
- DRUG Degarelix 80 mg / Degarelix 80 mg
- DRUG Degarelix 160 mg / Degarelix 160 mg
- DRUG Leuprolide 7.5 mg / Degarelix 80 mg
- DRUG Leuprolide 7.5 mg / Degarelix 160 mg
Study Locations (20)
Ontario
- The Female/Male Health Centres - Barrie
- Brantford Urology Research - Brantford
- Burlington Professional Centre - Burlington
- The Urology Research Centre - Burlington
- Investigational Site - Newmarket
California
- South Orange County Medical Research Center - Laguna Hills
- Western Clinical Research - Torrance
Florida
- South Florida Medical Research - Aventura
- Investigational Site - Ocala
North Carolina
- North Urology Research - Concord
- Investigational Site - Greensboro
Alabama
- Urology Centers Of Alabama - Homewood
Colorado
- Urology Associates Research - Englewood
Louisiana
- Regional Urology - Shreveport
New Jersey
- Lawrenceville Urology - Lawrenceville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451958
The ClinicalTrials.gov registry entry for NCT00451958 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (37% lower). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Degarelix 80 mg / Degarelix 80 mg is the first listed.
NCT00451958 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Ontario, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00451958 about?
NCT00451958 is a clinical study titled "A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy". Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
What is the current status of trial NCT00451958?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2007-03. Estimated completion is 2011-12.
What conditions does trial NCT00451958 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00451958?
The interventions under investigation include: Degarelix 80 mg / Degarelix 80 mg (DRUG), Degarelix 160 mg / Degarelix 160 mg (DRUG), Leuprolide 7.5 mg / Degarelix 80 mg (DRUG), Leuprolide 7.5 mg / Degarelix 160 mg (DRUG).
Who is sponsoring clinical trial NCT00451958?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00451958 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.